IDEAYA Biosciences, Inc. (IDYA) News
Follow IDEAYA Biosciences, Inc. (IDYA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 26 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
IDEAYA Biosciences Reports $125.7M Third-Quarter Net Loss
IDEAYA Biosciences reported third-quarter 2026 revenue of $10.2 million, down from $207.8 million a year earlier, when results included upfront Servier license revenue. Net loss was $125.7 million versus net income of $1
EQUITY | Nov 03, 2026, 09:13 PM UTC
M
IDEAYA Reports Q3 2026 Net Loss of $125.7 Million
IDEAYA reported $10.2 million in collaboration revenue and ended September with $1.15 billion in cash, cash equivalents and marketable securities. It maintained its cash runway guidance into 2030 and completed an NDA sub
EQUITY | Nov 03, 2026, 01:17 PM UTC
M
IDEAYA Biosciences Reports Q3 2026 Loss of $125.7 Million
IDEAYA reported $10.2 million in revenue, primarily from services under its darovasertib license agreement with Servier, and ended the quarter with approximately $1.15 billion in cash, cash equivalents and marketable sec
EQUITY | Nov 03, 2026, 12:34 PM UTC
M
IDEAYA Biosciences Q3 Revenue Estimate
IDEAYA Biosciences is scheduled to report Q3'26 results on November 10. The release time is not specified.
EQUITY | Nov 03, 2026, 12:00 PM UTC
M
Ideaya Biosciences Reports Q3 Loss
Ideaya Biosciences reported a net loss for the third quarter.
EQUITY | Nov 03, 2026, 11:56 AM UTC
M
IDEAYA Biosciences Posts Q3 Loss, Revenue Beats
IDEAYA Biosciences reported a Q3 loss of $1.22 per share, $0.04 worse than the FactSet consensus of $1.18 loss; revenue beat expectations.
EQUITY | Nov 03, 2026, 11:16 AM UTC
M
IDEAYA Biosciences Reports Third-Quarter 2026 Financial Results and Business Update
IDEAYA reported financial results for the quarter ended September 30, 2026, and provided a business update.
EQUITY | Nov 03, 2026, 11:02 AM UTC
M
IDEAYA Biosciences Reports Third-Quarter 2026 Results and Business Update
IDEAYA Biosciences reported its third-quarter 2026 financial results and provided a business update. The available body says ESMO 2026 data collectively supports the potential of darovasertib to become a foundation, but
EQUITY | Nov 03, 2026, 11:01 AM UTC
L
Weekly Recap: Stock option grants and Dr. Michael White promotion
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) bolstered its leadership and talent pool in late September 2026, promoting Dr. Michael White to President, R&D to steer its oncology precision—medicine and ADC programs while granti
EQUITY | Sep 28, 2026, 11:06 AM UTC
L
IDEAYA Biosciences, Inc. (IDYA) Promotes Dr. Michael White to President, R&D
IDEAYA Biosciences promoted Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective Sept. 28, 2026.Material DetailsContext by AI AnalystThis is a management evolution reinforcing
NEWS | Sep 28, 2026, 10:01 AM UTC
L
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 // -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the pro
NEWS | Sep 28, 2026, 10:00 AM UTC
L
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 // -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, o
NEWS | Sep 25, 2026, 10:00 AM UTC
M
IDeYA darovasertib NDA near completion; pipeline expands via new collaborations
IDEAYA says its darovasertib final NDA submission is imminent after positive FDA feedback, with new data to be presented at ESMO. Pipeline expansion includes a phase III DLL3 ADC trial and new Roche, PRMT5 and CDKN2A col
REGULATION | Sep 09, 2026, 05:20 PM UTC
L
IDYA darovasertib NDA nearing completion amid FDA feedback
IDEAYA Bio (IDYA) says a final NDA submission for darovasertib is imminent, with positive FDA feedback potentially enabling an all-comers label. Clinical and pipeline updates are slated for ESMO.
REGULATION | Sep 09, 2026, 04:29 PM UTC
L
IDEAYA Biosciences price target raised to $57 by Guggenheim
Guggenheim raised its price target on IDEAYA Biosciences to $57.00 per share from $54.00, according to Benzinga ratings coverage.
EQUITY | Sep 09, 2026, 01:21 PM UTC
M
IDYA and Servier dose first patient in OptimUM-11 Phase 3 uveal melanoma trial
IDEAYA Biosciences and Servier announced the first patient was dosed in OptimUM-11, a Phase 3 registrational trial evaluating darovasertib and crizotinib as adjuvant therapy for uveal melanoma.
EQUITY | Sep 09, 2026, 10:00 AM UTC
M
IDYA darovasertib nears NDA completion toward major U.S. milestones
Darovasertib is nearing NDA completion for metastatic uveal melanoma, with a potential U.S. launch in the first half of next year. PRMT5 and DLL3 pipeline assets are also advancing toward major data readouts and trial in
EQUITY | Sep 08, 2026, 07:59 PM UTC
L
Citizens maintains IDEAYA Biosciences price target at $42
Citizens maintained a $42.00 per-share price target for IDEAYA Biosciences.
EQUITY | Sep 01, 2026, 01:42 PM UTC
L
IDEAYA Biosciences to host London Investor R&D Day
IDEAYA Biosciences announced a London Investor R&D Day and plans to participate in September 2026 investor conferences.
EQUITY | Sep 01, 2026, 10:00 AM UTC
L
IDEAYA Biosciences announces Nasdaq Rule 5635(c)(4) inducement grants
IDEAYA Biosciences announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Aug 28, 2026, 10:01 AM UTC
H
Ideaya Biosciences, Genentech launch Phase 1 combo trial in KRAS G12D PDAC
Ideaya Biosciences (IDYA) announces a clinical collaboration with Genentech to sponsor a jointly governed trial and plan a Phase 1 combination cohort with Roche’s rg6505 in mtap-deleted, KRAS G12D mutant pancreatic cance
EQUITY | Aug 19, 2026, 10:34 AM UTC
L
IDEAYA Biosciences enters clinical collaboration with Genentech
IDEAYA Biosciences (IDYA) announces a clinical collaboration with Genentech focused on MTAP-deleted KRAS G12D-mutant pancreatic cancer.
EQUITY | Aug 19, 2026, 10:00 AM UTC
L
IDYA IDYA - IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
IDYA IDYA - IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 04, 2026, 10:00 AM UTC
L
IDEAYA Biosciences Announces Inducement Grants
IDEAYA Biosciences grants inducement awards
EQUITY | Jul 31, 2026, 10:00 AM UTC
L
IDYA Ideaya Biosciences announces ide892, a potential best-in-class mta-cooperative prmt5 inhibitor, initiates part 2 monotherapy expansion
IDYA Ideaya Biosciences announces ide892, a potential best-in-class mta-cooperative prmt5 inhibitor, initiates part 2 monotherapy expansion in the phase 1/2 study in mtap-deleted pancreatic and lung cancers
EQUITY | Jul 27, 2026, 10:27 AM UTC
L
Ideaya Biosciences Insider Sold Shares Worth $382,131, According to a Recent SEC Filing
() -- Briseno Andres Ruiz, Chief Accounting Officer, on July 07, 2026, sold 9,550 shares in Ideaya Biosciences (IDYA) for $382,131. Following the Form 4 filing with the SEC, Ruiz has control over a total of 26,466 common
REGULATION | Jul 09, 2026, 09:02 PM UTC